関連文献

Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy.

Diabetes Care. 36(5): 1248-1253, 2013.PubMed

Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.

Diabet Med. 29(8): e184-190, 2012.PubMed

Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.

Hypertens Res. 35(11): 1058-1062, 2012.PubMed

Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).

Internal Medicine. 50(12): 1273-1278, 2011.PubMed

Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

Hypertens Res . 34: 935-941, 2011.PubMed

Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.

Nephrol Dial Transplant. 26(7): 2127-2137, 2011.PubMed

Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.

Nephrol Dial Transplant. 26(11): 3465-3473, 2011.PubMed

Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.

Diabetes Care. 34(3): 691-696, 2011.PubMed

Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.

Eur J Clin Invest. 40(2): 95-102, 2010.PubMed

Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.

Diabetes Care. 33(6): 1320-1324, 2010.PubMed